Next-generation bioprocessing is a step-by-step evolution already well underway as the pharma industry undergoes a paradigm shift toward continuous processing. But companies don’t need to work in isolation; they can enhance their capacity to adapt to change and develop the necessary new technologies through fostering a robust extended network of partnerships.
Collaborative networks can enable more e·ective development of next-generation innovations and high-value bioprocessing technologies to meet industry needs. Each participant contributes valuable domain knowledge, strengthening the quality of information exchange. The ongoing feedback that each of these different collaborators provides can reduce uncertainty and “de-risk” the technology development process. These collaborations also assist in accessing ongoing regulatory guidance for successful implementation and validation.
To this end, MilliporeSigma is sharing its experience in building a collaboration network that incorporates a wide range of perspectives. Partners in this diverse network include biomanufacturers of different sizes, industry associations such as the BioPhorum Operations Group (BPOG) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIBML), academic researchers, and regulatory agencies such as the FDA and the European Medicines Agency (EMA).